ArticleDiscover oncology2025
Exosomal TACSTD2 promotes invasion, metastasis and glycolysis in ovarian cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTumour-derived exosomes are involved in various cancer processes, including invasion, metastasis, and tumour microenvironment (TME) remodelling. However, the function and mechanism of exosomes in ovarian cancer (OC) are still under investigation. The present study investigated the effects of tumour-derived exosomes on the carcinogenesis and progression of OC.
methodsOC gene expression profiles were obtained from The Cancer Genome Atlas (TCGA) database and two independent Gene Expression Omnibus (GEO) datasets (GSE7463 and GSE12470). The exosome related genes were obtained by intersecting with OC related exosomes in the ExoCarta database, subsequently, the exosome genes of interst were identified through performing survival analysis in the GEPIA database.The expression of genes selected were validated in OC cell lines (SKOV3, OVCAR3 and A2780) and ascites of OC patients through western blot and PCR. And further knockdown and overexpression of this gene were performed in OC cells to detect their effects on cell proliferation, migration, and invasion. Subsequently, the potential biological functions and regulatory mechanisms were explored based on the Gene Set Enrichment Analysis (GSEA), and changes in relevant target proteins were validated through western blot. Furthermore, SKOV3-luc + cells were injected intraperitoneally into female BALB/c nude mice to construct an in orthotopic xenograft mouse model, in order to evaluate the effect of differential genes on in vivo OC.
resultsBased on the results of bioinformatics analysis, TACSTD2 was selected for experimental validation. Cell function experiments verified that exosomal TACSTD2 promoted proliferation and metastasis by mediating glycolysis in OC. Animal experiments indicated that exosomal TACSTD2 promoted abdominal metastasis in OC. The in vitro and in vivo experimental results were consistent with the bioinformatics analysis.
conclusionTACSTD2, which can be detected in ovarian cancer-derived exosomes, plays an important role in the invasion, migration and glycolysis in ovarian cancer. Furthermore, we have discovered that TACSTD2 may promote the progression of ovarian cancer by regulating glycolysis. Further research will enable its potentially prognostic marker and therapeutic target for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.